

July 31, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter ended June 30, 2025.

The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com

This is for your information and records.

Yours sincerely,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above



Neuland Q1FY26 Total income at Rs.300.6 crore; EBITDA at Rs.42.1 crore

Hyderabad, India, July 31, 2025 – Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the first quarter ended June 30th, 2025.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“While Q1 FY26 has been below par as a result of the flow of customer orders, it doesn’t change our outlook on the healthy growth that we anticipate this financial year. The investments we have announced are proceeding according to plan and would be drivers of short as well as long term growth. We continue to focus on cost optimization opportunities across products and processes which will enable us to further strengthen our position in key products.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added *“We see substantial growth this year from our commercial molecules even as there is a significant influx of new business from existing and new customers along with customers’ pipeline projects making exciting progress. Given customers’ interest and evolving expectations we are continuing to invest in our people and capabilities which should see Neuland further differentiated as a CDMO with deep expertise as well as an agile innovative partner.”*

Financial Summary

Rs. crore					
Particulars (Rs Cr)	Q1FY26	Q1FY25	YoY (%)	Q4FY25	QoQ (%)
Total Income	300.6	444.4	-32.40%	335.8	-10.50%
EBITDA	42.1	128.6	-67.30%	58.2	-27.70%
EBITDA Margin	14.00%	28.90%	-1490 bps	17.30%	-330 bps
Exceptional Item*	-	20.6	-	-	-
Profit Before Tax*	17.4	130.3	-86.60%	39.0	-55.40%
PBT Margin	5.79%	29.30%	-2351 bps	11.60%	-580 bps
Profit After Tax	13.7	98.3	-86.10%	27.7	-50.50%

*Q1FY25 includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores.

Q1 FY26 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Thursday, July 31, 2025** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 980 Regulatory filings across the US (72 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com